Promising Adjunct Medicines in the Protocol of COVID-19 Clinical Trial

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative organism ofCOVID-19. Since this disease is considered new and does not have an approved curativeprotocol, many researchers have tackled the possible options for COVID-19 prevention andtherapeutic approaches. We address herein the phenomena of cytokine storm (the main causeof death) associating with the late stage of COVID19. Cytokine storm is undertaken in anattempt to provide information about its possible underlying causes, and to clarify some pointsthat can be of value in guiding treatment practices for a clinical trial.

Keywords

• covid-19
• drugs
• protocol